KFSHRC Introduces Pioneering Virtual Pathology Services in Madinah
17 nov. 2024 10h49 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Introduces Pioneering Virtual Pathology Services in Madinah
KFSHRC to Host Minimally Invasive Organ Transplant Consensus Conference in Riyadh
13 nov. 2024 08h45 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC to Host Minimally Invasive Organ Transplant Consensus Conference in Riyadh
Hyku Biosciences Appoints John Gustofson to its Board of Directors
12 nov. 2024 07h45 HE
|
Hyku Biosciences
John Gustofson, MS, MBA appointed to the Board of Directors The appointment is in conjunction with Chugai Venture Fund joining syndicate with an investment that brings Hyku’s total seed financing to...
Nodenza Venture Partners appoints George Freeman as Chair of Advisory Board
12 nov. 2024 07h00 HE
|
Nodenza Venture Partners
Nodenza Venture Partners appoints George Freeman as Chair of Advisory Board New York, November 12, 2024 – Nodenza Ventures Partners (“Nodenza”), today announces the appointment of George Freeman, MP,...
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11 nov. 2024 12h43 HE
|
AdipoPharma
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug,...
KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment
10 nov. 2024 07h26 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment
Olon ist bereit für die Produktion in der neuen Anlage für hoch starke Wirkstoffe
04 nov. 2024 05h00 HE
|
Olon SpA
MAILAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olon, ein Arzneimittelhersteller und globales CDMO-Unternehmen, bestätigt den Zeitplan für den Bau seiner neuen Produktionsanlage für hoch starke...
Olon est prête à lancer la production dans sa nouvelle installation dédiée aux composés ultra-puissants
04 nov. 2024 05h00 HE
|
Olon SpA
MILAN, 04 nov. 2024 (GLOBE NEWSWIRE) -- Olon, fournisseur d’API et acteur mondial dans le domaine des CDMO, confirme le respect du calendrier de construction de sa nouvelle installation dédiée aux...
Olon is ready to host productions in the new facility dedicated to ultra-potent compounds
04 nov. 2024 05h00 HE
|
Olon SpA
Olon is ready to host productions
in the new facility dedicated to ultra-potent compounds
Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities
28 oct. 2024 05h51 HE
|
SAI LIFE SCIENCES LIMITED
HYDERABAD, India, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has...